VRTX
NasdaqVERTEX PHARMACEUTICALS INC / MA
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$7.6B
2021
$8.9B
2022
$9.9B
2023
$11.0B
2024
$12.0B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$12.0B
Net Income$4.0B
Gross Profit—
Oper Income$4.2B
EPS (dil)$15.32
Rev/sh$47.29
FCF/sh$12.58
Book/sh$73.54
Gross M—
Oper M34.8%
Profit M32.9%
FCF M26.6%
ROE21.2%
ROA15.4%
ROIC26.0%
R&D/Rev25.4%
Rev Y/Y8.9%
Rev 3Y CAGR10.4%
EPS Y/Y836.5%
EPS 3Y CAGR6.1%
FCF 3Y CAGR-6.6%
Payout—
Div/sh—
Shs Chg Y/Y0%
Current Ratio2.90
Quick Ratio2.46
Debt/Eq0.01
Int Coverage313.8×
Net Debt$5.0B cash
Total Debt$105.0M
Cash & Eq$5.1B
Total Assets$25.6B
Oper CF$3.6B
Capex$437.6M
Free CF$3.2B
Buybacks$2.0B
Equity$18.7B
Liabilities$7.0B
Shs Outstand0.25B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $7.6B | $8.9B | $9.9B | $11.0B | $12.0B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $2.8B | $4.3B | $3.8B | $-232.9M | $4.2B |
| Net Income | $2.3B | $3.3B | $3.6B | $-535.6M | $4.0B |
| Diluted EPS | $9.01 | $12.82 | $13.89 | $-2.08 | $15.32 |
| Operating Cash Flow | $2.6B | $4.1B | $3.5B | $-492.6M | $3.6B |
| Free Cash Flow | $2.4B | $3.9B | $3.3B | $-790.3M | $3.2B |
COMMUNITY · $VRTX0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.